Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…-T cells, either alone or in combination with the ALK inhibitor lorlatinib. Tumor monitoring was performed weekly using IVIS imaging.Resul…
…05755Thomas SS, Gogas H, Hong YK, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and …
… the Institutional Animal Care and Use Committee (IACUC) of the University of California Irvine; approval number AUP22-092 and with a pending IRB.Abstract 455 …
…umber: NCT06865521). All patients were recruited and treated at West China Hospital of Sichuan University, where the study protocol was approved by the Institutional Rev…
… using the BAFF-CAR transposon construct. Patients then receive fludarabine (30 mg/m 2/d) and cyclophosphamide (500 mg/m2/d) lymphodepletio…
…for patients (pts) with advanced treatment-naïve or -refractory basal cell carcinoma (BCC). Annals of Oncology 33:S922-S923.Deutsch JS, Lai J, Schen…
…AR1302 (1mg/kg) was administered once per week for 3 weeks, and docetaxel (500µg) in 3 doses, every other day, for 1 week. Tumors, spleen…
…or regressions and a low incidence of Grade 3/4 adverse events. Melanoma patients with primary resistance to prior doublet immune checkp…
…arges, and inpatient mortality in hospitalized adults receiving immunotherapy.Methods We analyzed the National Inpatient Sample (NIS) from 20…
…okine and cytolysis molecule production (figure 2B).Conclusions REPO is a fluorescent small molecule that differentially stains T ce…
…0) • Mepolizumab 0 (0) • Benralizumab 1 (9) • Dupilumab 1 (9) • Tezepelumab 6 (55) • None 2 (18) Prior biological therapy use n% 0 4 (36) 1…